Zürcher Nachrichten - High hopes for nasal Covid vaccines despite 'disappointing' trial

EUR -
AED 4.101345
AFN 77.032505
ALL 99.346177
AMD 432.43567
ANG 2.013049
AOA 1036.77807
ARS 1075.022084
AUD 1.638665
AWG 2.009927
AZN 1.903727
BAM 1.957678
BBD 2.255263
BDT 133.478024
BGN 1.96194
BHD 0.420821
BIF 3237.947656
BMD 1.116626
BND 1.443284
BOB 7.718265
BRL 6.064287
BSD 1.116971
BTN 93.354568
BWP 14.765294
BYN 3.655406
BYR 21885.869656
BZD 2.251419
CAD 1.514765
CDF 3205.83349
CHF 0.948568
CLF 0.037681
CLP 1039.724056
CNY 7.877914
CNH 7.876551
COP 4648.301891
CRC 579.545486
CUC 1.116626
CUP 29.590589
CVE 110.369377
CZK 25.076404
DJF 198.897208
DKK 7.459169
DOP 67.044305
DZD 147.724424
EGP 54.187291
ERN 16.74939
ETB 129.612896
FJD 2.456911
FKP 0.850377
GBP 0.839089
GEL 3.048765
GGP 0.850377
GHS 17.559528
GIP 0.850377
GMD 76.478493
GNF 9650.126208
GTQ 8.634359
GYD 233.659928
HKD 8.702442
HNL 27.707575
HRK 7.591952
HTG 147.378717
HUF 393.677561
IDR 16934.414972
ILS 4.208201
IMP 0.850377
INR 93.284779
IQD 1463.20342
IRR 47001.617801
ISK 152.296414
JEP 0.850377
JMD 175.488318
JOD 0.791351
JPY 161.091169
KES 144.067258
KGS 94.062898
KHR 4536.351005
KMF 492.822874
KPW 1004.96277
KRW 1492.18639
KWD 0.340616
KYD 0.930801
KZT 535.514042
LAK 24664.21472
LBP 100022.944684
LKR 340.786863
LRD 223.390262
LSL 19.608883
LTL 3.297107
LVL 0.675436
LYD 5.304278
MAD 10.830976
MDL 19.490869
MGA 5051.754868
MKD 61.661441
MMK 3626.7577
MNT 3794.295108
MOP 8.965839
MRU 44.388973
MUR 51.230572
MVR 17.151745
MWK 1936.622809
MXN 21.621786
MYR 4.695396
MZN 71.296513
NAD 19.608708
NGN 1830.652829
NIO 41.108877
NOK 11.731586
NPR 149.370267
NZD 1.791604
OMR 0.429846
PAB 1.116951
PEN 4.186559
PGK 4.37235
PHP 62.154728
PKR 310.35047
PLN 4.275394
PYG 8714.358307
QAR 4.072206
RON 4.974455
RSD 117.081921
RUB 103.595912
RWF 1505.75772
SAR 4.190263
SBD 9.275742
SCR 15.20849
SDG 671.658527
SEK 11.379804
SGD 1.442608
SHP 0.850377
SLE 25.511892
SLL 23415.083225
SOS 638.317954
SRD 33.334619
STD 23111.9038
SVC 9.773243
SYP 2805.55626
SZL 19.61599
THB 36.878746
TJS 11.873175
TMT 3.908191
TND 3.384446
TOP 2.615244
TRY 38.089784
TTD 7.597151
TWD 35.731768
TZS 3046.939603
UAH 46.168836
UGX 4138.117278
USD 1.116626
UYU 46.153648
UZS 14213.632892
VEF 4045036.356711
VES 41.049924
VND 27474.582801
VUV 132.568082
WST 3.12372
XAF 656.574989
XAG 0.035614
XAU 0.000427
XCD 3.017737
XDR 0.827794
XOF 656.577931
XPF 119.331742
YER 279.519396
ZAR 19.564743
ZMK 10050.970555
ZMW 29.570833
ZWL 359.553117
  • CMSD

    0.0300

    25.01

    +0.12%

  • CMSC

    0.0650

    25.12

    +0.26%

  • BCC

    7.6300

    144.69

    +5.27%

  • NGG

    -1.2200

    68.83

    -1.77%

  • BCE

    -0.4200

    35.19

    -1.19%

  • SCS

    -0.8000

    13.31

    -6.01%

  • GSK

    -0.8100

    41.62

    -1.95%

  • RIO

    2.2700

    65.18

    +3.48%

  • BTI

    -0.3100

    37.57

    -0.83%

  • AZN

    0.3200

    78.9

    +0.41%

  • RBGPF

    60.5000

    60.5

    +100%

  • JRI

    -0.0400

    13.4

    -0.3%

  • RYCEF

    -0.0200

    6.93

    -0.29%

  • BP

    0.3300

    32.76

    +1.01%

  • RELX

    0.7600

    48.13

    +1.58%

  • VOD

    -0.1700

    10.06

    -1.69%

High hopes for nasal Covid vaccines despite 'disappointing' trial
High hopes for nasal Covid vaccines despite 'disappointing' trial / Photo: TIM SLOAN - AFP/File

High hopes for nasal Covid vaccines despite 'disappointing' trial

Nasal vaccines could still be a powerful future weapon in the fight against Covid-19 despite "disappointing" recent trial results for an AstraZeneca spray, experts say.

Text size:

By entering the body the same way as the virus, nasal vaccines aim to build immunity in the mucous membrane that lines the nose and mouth.

This could block people from getting infected in the first place -- and also potentially hamper those who have Covid from spreading it further.

That would represent a huge boost compared to traditional shots in the arm, which have proved very effective at preventing severe Covid but perform far less well when it comes to stopping transmission.

Last month China became the first country to approve a needle-free Covid vaccine, an aerosolised mist inhaled through the nose and mouth using a nebuliser device, while India greenlit a homegrown nasal drop vaccine days later.

With some wondering when Western nations would catch up, last week Oxford researchers revealed the results of a phase 1 trial for a simple nasal spray using the AstraZeneca vaccine.

However, the vaccine promoted mucosal antibodies only in a minority of the participants, and the immune responses were weaker compared to those from traditional vaccines, according to a study published in the journal eBioMedicine.

- Don't be 'too downhearted' -

"The nasal spray did not perform as well in this study as we had hoped," said the trial's chief investigator, Sandy Douglas of Oxford University.

"This was quite different from recent data from China, which has suggested good results can be achieved by delivery of a similar vaccine deep into the lungs with a more complex nebuliser device," Douglas said in a statement.

"One possibility is simply that the majority of the nasal spray vaccine ends up being swallowed and destroyed in the stomach -- delivery to the lungs could avoid that."

Connor Bamford, a virologist at Queen's University Belfast, told AFP that it was important to "not be too downhearted" about the AstraZeneca results.

He said that working out exactly why the nasal spray fell short could help researchers discover how to make a future version more effective.

Unlike AstraZeneca, successful nasal vaccines used for other diseases such as polio, rotavirus and influenza are all live vaccines, which means they replicate inside the nose, Bamford said, potentially pointing a way forwards for researchers.

Eric Tartour, an immunologist at the European Hospital Georges Pompidou in Paris, said that while the AstraZeneca results "are indeed disappointing", he did not think the news "dampens hope for nasal vaccines".

It was "reassuring" that the AstraZeneca, Chinese and Indian nasal vaccines have not shown any serious side effects, he added.

Around 100 different intranasal Covid vaccines are under development worldwide, according to analysis by health data firm Airfinity and Nature last month, with some 20 being tested on humans.

Russia and Iran have also approved nasal vaccines. However, like China and India, they have not published trial data showing that their vaccines stop transmission in a peer-reviewed journal.

And with falling inoculation rates worldwide leading some countries to destroy millions of expired doses, the demand for a new Covid vaccine remains unclear.

- 'Wake up and lead' -

For example, in 2020 France's Pasteur Institute and biotech firm TheraVectys developed a nasal vaccine candidate that was found to block transmission and produce antibodies for different variants in tests on animals, according to chief scientific officer Pierre Charneau.

However, the vaccine has not "aroused enough interest from funding agencies or 'Big Pharma' to hold trials on humans," so the firm has turned its focus back towards cancer vaccines, Charneau said.

US biotech firm Meissa Vaccines has developed a nasal vaccine shown to produce an immune response in phase 1 trials on humans, said its chief scientific officer Martin Moore.

So how long could it take for such a nasal vaccine to be made available to the public? It depends, Moore said.

He called for the world to put similar resources into creating a nasal vaccine as it did into the first round of Covid jabs, which were developed and deployed en masse in less than a year -- the fastest rate in history.

"If there was a Warp Speed 2.0, and there should be, our vaccine could be available to the public with a similar timeline," Moore said.

"Reducing transmission is the best way to gain control over the virus," Moore said. "The challenge is proving that a nasal vaccine can actually do this," he added.

"The upside to our health and economies is enormous. Western countries need to wake up and lead."

W.Vogt--NZN